成人重症监护患者谵妄使用氟哌啶醇的患病率及相关危险因素:多国AID-ICU起始队列研究
该多国起始队列研究纳入13个国家99个ICU的1260例急性入院的成人ICU患者,在2周起始期内筛查谵妄并随访90天死亡率。谵妄发生率为25%(23-27),其中46%(41-52)使用氟哌啶醇,苯二氮卓类36%、右美托咪定21%、喹硫平19%、奥氮平9%亦被用于谵妄。入ICU24小时内所有谵妄亚型及循环支持与氟哌啶醇使用相关,72小时时循环支持仍与后续氟哌啶醇使用相关。氟哌啶醇使用与90天死亡率无统计学显著关联。
要点
- 谵妄发生于314/1260例(25%,95%CI 23-27),其中145例(46%,95%CI 41-52)接受氟哌啶醇治疗。
- 入ICU24小时内,多动型谵妄与氟哌啶醇使用的aOR为29.7(95%CI 12.9-74.5),混合型aOR 10.0(5.0-20.2),低活动型aOR 3.0(1.2-6.7)。
- 入ICU24小时内循环支持与氟哌啶醇使用相关,aOR 2.7(95%CI 1.7-4.3);72小时时循环支持仍与后续氟哌啶醇使用相关,aOR 2.6(95%CI 1.1-6.9)。
- 氟哌啶醇使用与90天死亡率无统计学显著关联:0-24小时内使用aOR 1.2(95%CI 0.5-2.5),p=0.66;0-72小时内使用aOR 1.9(95%CI 1.0-3.9),p=0.07。
- 谵妄的其他干预包括苯二氮卓类36%(31-42)、右美托咪定21%(17-26)、喹硫平19%(14-23)、奥氮平9%(6-12)。
适用人群与场景
- 急性入院的成人ICU患者,来自13个国家99个ICU,在2周起始期内纳入。
处置流程与药物剂量
- 谵妄患者中使用的药物包括氟哌啶醇(46%)、苯二氮卓类(36%)、右美托咪定(21%)、喹硫平(19%)、奥氮平(9%),原文未报告具体剂量、给药途径和频次。
研究设计与关键结果
- 研究类型为多国起始队列研究,纳入1260例患者,来自99个ICU(13个国家),谵妄发生率为25%(95%CI 23-27)。
- 谵妄患者中145例(46%,95%CI 41-52)接受氟哌啶醇治疗。
- 入ICU24小时内,多动型谵妄aOR 29.7(95%CI 12.9-74.5)、混合型aOR 10.0(5.0-20.2)、低活动型aOR 3.0(1.2-6.7)与氟哌啶醇使用相关;循环支持aOR 2.7(1.7-4.3)。
- 入ICU72小时时,循环支持仍与后续氟哌啶醇使用相关,aOR 2.6(95%CI 1.1-6.9)。
- 氟哌啶醇使用与90天死亡率无统计学显著关联:0-24小时内aOR 1.2(95%CI 0.5-2.5),p=0.66;0-72小时内aOR 1.9(95%CI 1.0-3.9),p=0.07。
证据类型、等级与局限
- 证据类型:多国起始队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论指出氟哌啶醇是成人谵妄患者的主要药物治疗选择,且使用与90天死亡率无统计学显著关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality.
METHODS: All acutely admitted, adult ICU patients were screened during a 2-week inception period. We followed the patient throughout their ICU stay and assessed 90-day mortality. We assessed patients and their variables in the first 24 and 72 h in ICU and studied their association together with that of ICU characteristics with haloperidol use.
RESULTS: We included 1260 patients from 99 ICUs in 13 countries. Delirium occurred in 314/1260 patients [25% (95% confidence interval 23-27)] of whom 145 received haloperidol [46% (41-52)]. Other interventions for delirium were benzodiazepines in 36% (31-42), dexmedetomidine in 21% (17-26), quetiapine in 19% (14-23) and olanzapine in 9% (6-12) of the patients with delirium. In the first 24 h in the ICU, all subtypes of delirium [hyperactive, adjusted odds ratio (aOR) 29.7 (12.9-74.5); mixed 10.0 (5.0-20.2); hypoactive 3.0 (1.2-6.7)] and circulatory support 2.7 (1.7-4.3) were associated with haloperidol use. At 72 h after ICU admission, circulatory support remained associated with subsequent use of haloperidol, aOR 2.6 (1.1-6.9). Haloperidol use within 0-24 h and within 0-72 h of ICU admission was not associated with 90-day mortality [aOR 1.2 (0.5-2.5); p = 0.66] and [aOR 1.9 (1.0-3.9); p = 0.07], respectively.
CONCLUSIONS: In our study, haloperidol was the main pharmacological agent used for delirium in adult patients regardless of delirium subtype. Benzodiazepines, other anti-psychotics and dexmedetomidine were other frequently used agents. Haloperidol use was not statistically significantly associated with increased 90-day mortality.
参考来源
- Collet MO, Caballero J, Sonneville R, et al. Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study. Intensive Care Med. 2018. PMID: 29767323. doi:10.1007/s00134-018-5204-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。